news
A view shows Ambuja Cement bags, to be carried to a construction site, in a load carrier in Ahmedabad, India, July 29, 2022. REUTERS/Amit Dave/

 

Cyril Amarchand Mangaldas has advised Adani Group’s Ambuja Cement on its acquisition of a majority stake in cement manufacturer Sanghi Industries, which was counselled by Khaitan & Co.

As per the agreement, Ambuja Cement, India’s second-largest cement producer, will buy close to a 57 percent stake in Sanghi, valued at over $600 million, from its existing promoter group led by Ravi Sanghi.

The CAM team was led by partners Ruetveij Pandya and Jeeta Nayak. Finance partner Atman Desai and the firm’s antitrust head Avaantika Kakkar also supported the deal.

Khaitan’s team advising Sanghi Infrastructure was led by public M&A partner Abhishek Dadoo. Khaitan’s M&A head Haigreve Khaitan advised on deal structuring. Partners Anshuman Sakle (antitrust), Shivanshu Thaplyal (mining), Harsh Parikh (real estate) and Smita Jha (finance) also assisted on the deal. Partner Mehul Shah advised on merger-related-structuring issues.

CAM advised the Adani Group when it entered the Indian cement sector last year with a $10.5 billion deal to buy Ambuja and ACC from Swiss giant Holcim.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Nishimura continues SEA growth with energy partner

by Nimitt Dixit |

Japanese Big Six law firm Nishimura & Asahi has continued the planned expansion of its Southeast Asia offerings with the addition of energy-focused finance and M&A partner Sean Conaty.

GT, Goodwin act as Japan's Ono buys U.S. drugmaker for $2.4 bln

Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of  U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.

R&T, WongP, Lee & Lee advise on $595 mln TCM deal

by Nimitt Dixit |

Singapore law firms WongPartnership, Lee & Lee and Rajah & Tann (R&T), and R&T’s Malaysian member firm Christopher & Lee Ong have advised traditional Chinese medicine firm Eu Yan Sang International (EYS) and its shareholders on the sale of 86 percent of EYS’ shares.